Cellceutix Corporation announced that approximately 75% of the subjects enrolled in the Company's Phase 2 clinical trial of Prurisol for the treatment of chronic plaque psoriasis have completed dosing, defined as 84 days of daily treatments of Prurisol or placebo. A The subjects will now be followed for an additional 4 weeks, without taking any further study medication. The four-arm multi-center Phase 2 trial, three arms with different dosing regimens of Prurisol and one armA placebo, is designed to assess the efficacy and safety of Prurisol given orally compared to placebo in a randomized, double-blind setting in patients with mild to moderate chronic plaque psoriasis.

The trial was expected to enroll 100 subjects and actually enrolled 115 subjects. The primary efficacy endpoint will be the percentage of subjects with greater than or equal to a 2-point improvement in Investigator's Global Assessment (IGA) rating as defined by visual inspections of patient lesions. The final study visit for the last subject is expected early in April 2016, with top-line data anticipated approximately four weeks later.